An interventional study of Optical Coherence Tomography in Parkinson's Disease and Visual Hallucinations, sponsored by University Hospital, Clermont-Ferrand. Status unknown at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-13.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science
Parkinson's disease is characterized not only by motor symptoms but also by psycho-behavioral symptoms including Visual Hallucinations (VH) and illusions (I), that are generally associated with a severe functional impairment and a bad prognosis for patients. Visual Hallucinations are defined by a visual perception without any real objet to perceive, whereas illusions are defined by a wrong perceptions of an object that is really present. In most of studies investigating the pathophysiology of VH in PD, no difference is made between VH and I, however different mechanisms could lead to the emergence of these two phenomenon, with different prognosis.
Investigator hypothesize that illusions could be related to a visual impairment, maybe at the retinal level, known to be impaired in PD, whereas Visual hallucinations would be due to a more widespread impairment affecting higher levels visuo-perceptive and cognitive functions.
Parkinson's disease is a neurodegenerative disorder characterized by tremor, rigidity and akinesia, but patients can also present various non-motor symptoms in the course of their illness, including visual hallucinations, delusions or illusions. Visual Hallucinations are false perceptions (no external stimulus is present; generally caused by internal stimulations), whereas illusions are defined by a wrong perception (an external stimulus is always present). Delusions are false believes .The occurrence of hallucinations in PD is of major importance as it has been shown to be associated with an increased risk of cognitive impairment and could lead to nursing home placement and to increased mortality. It is generally believed that delusions/illusions also imply a bad prognosis with time . However recent data suggest that delusions/illusion are not associated with such a poor outcome regarding cognitive functions and mortality compared to hallucinations suggesting different pathological mechanisms and anatomical substrates . Also, a recent study analyzing the neuropsychological correlates of minor hallucinations in PD did not find executive dysfunction to contribute to the onset of minor psychotic phenomena, but was specifically implicated in the progression to well-structured VH.
Thus illusions and minorVH may have a different pathogenesis and a different prognosis compared to complex VH, however studies exploring the structural and functional changes associated with hallucinations in PD have mainly included patients with well-structured VH and moderate to severe cognitive impairment , making it difficult to define early abnormalities associated with minor hallucinations or illusions.
Several hypotheses are proposed regarding the emergence of hallucinations in PD.
Thus, the emergence of VH and illusions in PD could be due to an inbalance between a hypoactivated "bottom-up" (due to retino-striato-occipital hypoactivation) and a deshinibited "top-down" (mainly frontal) visual stream. However in all these studies, Hallucinations and illusions were not specifically discriminated and investigated in spite of the fact that they could be subtended by different pathophysiological mechanisms and might imply different prognosis for the evolution of the disease.
Investigator hypothesize that illusions, which represent the failure to successfully integrate stimuli that have been physically presented, could be more related to "bottom up" impairment, unlike Hallucinations, which occur where there is perception in the absence of any stimulus and could be more related to a "top down" impairment. Thus, PD patients with illusions (PD-I) might present greater retinal degeneration measured by OCT compared to PD patients with Visual hallucinations (PD-VH) and PD patients without Hallucinations or illusion (PD-nVHI), suggesting a sensorial deprivation underlying these disturbed visual perceptions of reality. Visual Hallucinations that are more elaborated would require a more widespread cognitive disorder, with increased cognitive and visuoperceptive dysfunction.
OBJECTIVE In this study investigator aim to compare PD patients with visual hallucinations (PD-VH), with illusions (PD-I), without Visual hallucinations or illusions (PD-nVHI) regarding retinal degeneration in OCT and cognitive functions (visuoperceptive and attentional functions) in order to determine whether PD-I might show greater retinal degeneration compared to PD-VH, and lesser cognitive impairment.
DESIGN OF STUDY:
Investigator will include 30 PD-VH+, 30 PD-I+, 30 PD-VH-I- among the patients consulting at our center.
During the first visit (Baseline, inclusion visit, 2 hours), each subject will perform a clinical and neurological examination with : • Diagnosis of PD according to UKPDBB criteria.
During the second visit (Day 15, one day), each patient will have a neurological, neuropsychological and ophthalmological examination with an evaluation of
Circumstances of emergence and distress caused by Hallucinations/illusions was also evaluated by measurement of heart rate variability, electrodermal recording, spy glasses and self-evaluation of Stress.
Finally, each subject will have a Magnetic Resonance Imaging (MRI) acquisition.
Exclusion Criteria:
PD patients without hallucinations or illusions
Diagnostic Test: Optical Coherence Tomography
PD patients with Illusions and without hallucinations
Diagnostic Test: Optical Coherence Tomography
PD patients without Illusions and with hallucinations
Diagnostic Test: Optical Coherence Tomography
The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
Total and segmental Retinal thickness (in microns) measured with Optical Coherence Tomography
Measurement of different retinal layers using Optical coherence tomography
Time frame: at day 15
Characteristics and severity of hallucinations/illusions using Psychosensory Hallucination Scale
Four domains (auditory, visual, olfactory and gustatory, cenesthetic hallucination modalities) are defined with nonoverlapping items
Time frame: at baseline
Characteristics and severity of hallucinations/illusions measured using the University of Miami Parkinson's Disease Hallucinations Questionnaire
Time frame: at baseline
Cognitive function evaluated by the Montreal Cognitive Assessment
Time frame: at day 15
Dementia evaluated by the Mattis Dementia Rating Scale
It generates five subscale scores in the areas of Attention, Initiation-Perseveration, Construction, Conceptualization, and Memory.
Time frame: at day 15
Best corrected visual acuity measured by Parinaud scale
Parinaud scale measures the best corrected near visual acuity, the best outcome is P2 and the worth \<P24.
Time frame: at day 15
Intraocular pressure measured with air pulse tonometer
Time frame: at day 15
Contrast sensitivity measured using the Vistech test
Time frame: at day 15
Color vision measured using the Test 15 Hue de Farnsworth
Time frame: at day 15
Parkinsonian syndrome severity measured with the MDS UPDRS Scale
The full MDS-UPDRS contains questions/evaluations, divided across Part I (Non-Motor Aspects of Experiences of Daily Living), Part II (Motor Aspects of Experiences of Daily Living), Part III (Motor Examination : 33 scores based on 18 items, several with right, left or other body distribution scores), and Part IV (Motor Complications).
Time frame: at day 15
Parkinsonian syndrome severity measured by the Hoehn and Yahr score
Time frame: at day 15
Sleep quality measured by the Parkinson's Disease Sleep Scale
This scale allows to self-rate and quantify the level of sleep disruption being experienced. It rates 15 items that have 0 to 4 options, 4 is the worth option.
Time frame: at day 15
Vigilance measurement and sleep Attack research using the Epworth test
Time frame: at day 15
Volume of grey matter area (frontal , parietal, occipital, mesencephalic cortex area ) measured at the time of Magnetic Resonance Imaging
Time frame: at day 15
Emergence of Hallucinations/illusions and distress measured by heart rate variability
Time frame: at day 15
Emergence of Hallucinations/illusions and distress measured by electro dermal recording
Time frame: at day 15
Emergence of Hallucinations/illusions and distress measured by self-evaluation of Stress questionnaire
Time frame: at day 15
Emergence of Hallucinations/illusions and distress measured by spy glasses questionnaire
Time frame: at day 15
This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand